-
Nothing but TimeA father with metastatic kidney cancer embraces moments with his 3-year-old son while pondering how he'll be remembered.
by Adam P. Stern
-
New Drugs for an Elusive Cancer TargetMedical oncologist and lung cancer expert Roy S. Herbst discusses early data on drugs that target a mutated form of the KRAS protein.
by Anna Azvolinsky
-
Cancer Patient Advocates Find Strength in NumbersPatient advocates have become a vital part of the San Antonio Breast Cancer Symposium. Opportunities for advocates continue to multiply.
by Marci A. Landsmann
-
Exploring Immunotherapy for Triple Negative Breast CancerFollowing the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.
by Marci A. Landsmann
-
Possible New Treatments for Patients With Metastatic HER2-Positive Breast CancerStudies presented at the San Antonio Breast Cancer Symposium show additional treatment options.
by Marci A. Landsmann
-
A Switch From Intravenous to Oral Chemo?Compared with intravenous paclitaxel, the oral form of the chemotherapy drug was associated with improved tumor shrinkage in metastatic breast cancer patients.
by Ashley P. Taylor
-
Navigating Hospital Discharge DecisionsPatients with advanced cancer often go to rehabilitation facilities after a hospital stay in hopes of gaining the strength for further treatment, but the majority do not go on to receive additional cancer therapy, a study reports.
by Ashley P. Taylor
-
Immunotherapy in the ElderlyImmune checkpoint inhibitors can be effective treatments for elderly people with some types of advanced cancer, but more information is needed on their risks and benefits in this group.
by Emma Yasinski
-
First Immunotherapy Approved for Breast CancerMedical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.
by Anna Azvolinsky
-
The Genetics of Metastatic CancerThe multiple tumors in patients with metastatic disease share key genetic traits, a sequencing study shows.
by Anna Azvolinsky
Adding chemotherapy to targeted therapy improves outcomes for people with advanced EGFR-positive non-small cell lung cancer.
by Sandra Gordon
Lessons From 20 Years Living With CancerMultiple myeloma survivor Jonathan Gluck reflects on uncertainty, and the scientific progress that has kept him living with cancer for more than two decades.
by Eric Fitzsimmons
The Enduring Importance of Cancer Disparities ResearchOpening session from AACR conference highlights how perseverance and adversity have informed cancer disparities research over the years.
by Eric Fitzsimmons
Most Cancer Survivors Don’t Meet Healthy Diet GoalsDespite research linking fruits and vegetables to cancer survival, many people do not change their eating habits after diagnosis.
by Darlene Dobkowski
-
Keeping Hope Alive—Why the Schlueters Rally for Medical ResearchRichard and Michelle Schlueter attended the Rally for Medical Research to advocate for NIH funding after budget cuts delayed his treatment.
-
Cancer in the Rearview Mirror: 15 Years of AACR Cancer Progress Report Survivor StoriesCancer survivors profiled over the past 15 years in the AACR Cancer Progress Reports shared updates on their lives and the progress made against cancer.
Cancer Research at a Crossroads
